AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jun 12, 2018
33422_dirs_2018-06-12_57381cad-4868-4397-b46f-75ffc237b7a6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-08
Reporting Person: TRABER PETER G (President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-08 | Common Stock | M | 70000 | $.87 | Acquired | 177333 | Direct |
| 2018-06-08 | Common Stock | S | 70000 | $5.8571 | Disposed | 107333 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-06-08 | Stock option (right to buy) | $.87 | M | 70000 | Disposed | 2026-12-03 | Common Stock (70000) | Direct |
Footnotes
F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018.
F2: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.
F3: The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.